Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
The Effect of SAAE on Vascular Endothelial Function in PA Patients
- Conditions
- Primary Aldosteronism
- Interventions
- Procedure: Super selective adrenal artery embolization
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 200
- Registration Number
- NCT05561361
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, China
The Effect of SAAE on Ventricular Remodeling in PA Patients
- Conditions
- Primary Aldosteronism
- Interventions
- Other: Super selective adrenal artery embolization
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 112
- Registration Number
- NCT05501080
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, China
A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)
- Conditions
- Polycystic Ovary Syndrome (PCOS)
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Fundació Sant Joan de Déu
- Target Recruit Count
- 364
- Registration Number
- NCT05394142
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
🇪🇸Hospital Sant Joan de Deu, Esplugues De Llobregat, Spain
🇪🇸Hospital Universitari de Girona Dr. Trueta, Girona, Spain
Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
- Conditions
- Aortic Stenosis, Severe
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- University Medical Center Goettingen
- Target Recruit Count
- 300
- Registration Number
- NCT05230901
- Locations
- 🇩🇪
University Medical Center Göttingen, Göttingen, Lower Saxony, Germany
Spironolactone in CKD Enabled by Chlorthalidone: PILOT
- Conditions
- Renal InsufficiencyChronic Hypertension
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Indiana Institute for Medical Research
- Target Recruit Count
- 24
- Registration Number
- NCT05222191
- Locations
- 🇺🇸
Richard L Roudebush VA Medical Center, Indianapolis, Indiana, United States
Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 154
- Registration Number
- NCT05092984
- Locations
- 🇫🇷
University Hospital, Strasbourg, France, Strasbourg, Alsace, France
Transgender Estradiol Affirming Therapy
- Conditions
- Transgenderism
- Interventions
- Diagnostic Test: Pro-thrombotic markersDrug: Transdermal patchDiagnostic Test: Metabolic markersDiagnostic Test: Hormone ProfileDrug: Daily Sublingual TabletDrug: BID Sublingual Tablet
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 39
- Registration Number
- NCT05010707
- Locations
- 🇺🇸
Washington University Transgender Center, Saint Louis, Missouri, United States
Fibrosis and the Fontan
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 120
- Registration Number
- NCT04901975
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Non-Responsive Diabetic Macular Edema and Spironolactone
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT04853355
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19
- Conditions
- Coronavirus InfectionPneumonia, Viral
- Interventions
- Drug: Standard-of-care SARS-CoV-2 treatment
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chita State Regional Clinical Hospital Number 1
- Target Recruit Count
- 440
- Registration Number
- NCT04826822
- Locations
- 🇷🇺
Chita State Regional Clinical Hospital Number 1, Chita, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.